Page 24:"Given the focus on neurology assets and blockbuster indications by pharmaceutical companies, Argenica is well positioned to partner post Phase 2"
Page 16: "A 1.6% decrease in infarct volume (decrease in brain cell death) is the minimum amount of decrease deemed to be clinically important. This decrease, on average, results in 1.3 more patients achieving out of 100 achieving functional independence (mRS 0-2).
Studies have shown a decrease of 5%, 11.5% and 17% would results in 5, 10 and 15 more patients out of 100, respectively, achieving functional independence (mRS of 0-2). This means 5, 10 and 15 more patients per 100 who would move from being severely or moderately disabled to having no or only a slight disability." (Argenica is showing a 70% reduction)
Three years' worth of work for the same price then as it is today (you can thank the interest rate increases sucking money out of the small cap market). Once we push past that heavy zone of overhead resistance it should be an explosive re-rate to a new trading range well north of here.
AGN Price at posting:
73.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)